BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2423280)

  • 1. Suppression of natural and activated human antitumour cytotoxicity by human seminal plasma.
    Rees RC; Vallely P; Clegg A; Potter CW
    Clin Exp Immunol; 1986 Mar; 63(3):687-95. PubMed ID: 2423280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seminal plasma suppression of human lymphocyte responses in vitro requires the presence of bovine serum factors.
    Vallely PJ; Rees RC
    Clin Exp Immunol; 1986 Oct; 66(1):181-7. PubMed ID: 3492315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of natural killer cell activity by human seminal plasma in vitro: identification of 19-OH-PGE as the suppressor factor.
    Tarter TH; Cunningham-Rundles S; Koide SS
    J Immunol; 1986 Apr; 136(8):2862-7. PubMed ID: 3754269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells.
    Kedar E; Rezai AR; Giorgi JV; Gale RP; Champlin RE; Mitsuyasu RT; Fahey JL
    Nat Immun Cell Growth Regul; 1988; 7(1):13-30. PubMed ID: 2896298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
    Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A
    Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
    Chong AS; Scuderi P; Grimes WJ; Hersh EM
    J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB; Gutterman JU; Grimm EA
    Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
    Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
    J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity.
    Gan X; Zhang L; Solomon GF; Bonavida B
    Brain Behav Immun; 2002 Jun; 16(3):227-46. PubMed ID: 12009684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells.
    Condiotti R; Nagler A
    Exp Hematol; 1998 Jul; 26(7):571-9. PubMed ID: 9657131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
    Frey JR; Kamber M; Peck R
    Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated and natural killer cell activity in human intestinal mucosa.
    Hogan PG; Hapel AJ; Doe WF
    J Immunol; 1985 Sep; 135(3):1731-8. PubMed ID: 3926882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.
    Ortaldo JR; Mason AT; Gerard JP; Henderson LE; Farrar W; Hopkins RF; Herberman RB; Rabin H
    J Immunol; 1984 Aug; 133(2):779-83. PubMed ID: 6203980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
    Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
    J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of IL-2, IL-12 and IL-18 on cytolytic activity, perforin expression and IFN-gamma production of porcine natural killer cells.
    Pintaric M; Gerner W; Saalmüller A
    Vet Immunol Immunopathol; 2008 Jan; 121(1-2):68-82. PubMed ID: 17913242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.